



## Intellia Therapeutics to Present at February Healthcare Investor Conferences

January 31, 2018

CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one meetings at the following upcoming healthcare conferences in February:

### Wednesday, February 14, 2018

#### Leerink Partners 7<sup>th</sup> Annual Healthcare Conference

Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences

Location: New York, New York

Presentation Time: 1:00pm EST

### Tuesday, February 27, 2018

#### Credit Suisse 2018 Global Healthcare Conference

Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences

Location: London, United Kingdom

One-on-one meetings only

A live webcast of Intellia's presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at [www.intelliatx.com](http://www.intelliatx.com). To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia's website for 14 days following each conference.

### About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at [intelliatx.com](http://intelliatx.com); Follow us on Twitter [@intelliatweets](https://twitter.com/intelliatweets)

### Investor Contact:

Lindsey Trickett  
Vice President, Investor Relations

+1 857-285-6211

[lindsey.trickett@intelliatx.com](mailto:lindsey.trickett@intelliatx.com)

### Media Contact:

Jennifer Mound Smoter  
Senior Vice President, External  
Affairs &

Communications

+1 857-706-1071

[jenn.smoter@intelliatx.com](mailto:jenn.smoter@intelliatx.com)



Source: Intellia Therapeutics, Inc.